Alta Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alta Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-800	Closed	-$65.9K	–	417
2024 Q2	$65.9K	Hold	800	–	–	0.03%	350
2024 Q1	$69.9K	Hold	800	–	–	0.03%	341
2023 Q4	$77.1K	Hold	800	–	–	0.04%	313
2023 Q3	$70.8K	Hold	800	–	–	0.04%	311
2023 Q2	$69.3K	Hold	800	–	–	0.04%	330
2023 Q1	$77.8K	Hold	800	–	–	0.05%	303
2022 Q4	$83K	Hold	800	–	–	0.05%	275
2022 Q3	$68K	Buy	+800	New	+$71.2K	0.04%	316

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Alta Advisers's BMRN Position: Q3 2024 in Review

Alta Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 800 shares — an estimated $65.9K sold.

Alta Advisers first reported a position in BMRN in Q3 2022 and held it in 8 quarters. The position peaked at $83K in Q4 2022. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Alta Advisers reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Alta Advisers sold 800 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $65.9K.
Alta Advisers first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 8 quarters.
Alta Advisers's BioMarin Pharmaceuticals position peaked at $83K in Q4 2022.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Alta Advisers's 13F filing for Q3 2024, filed 8 Nov 2024.